Background illustration for clinical trials search

Paid Clinical Trials Tacoma

Discover 1,438 paid clinical trials in Tacoma, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for
Ganglioneuroblastoma, Nodular, Neuroblastoma
Location: Tacoma WA, Seattle WA, Portland OR, Vancouver,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 30

Code: NCT06172296

Phase3, Recruiting

Project: Every Child for Younger Patients With Cancer

for
Adrenal Gland Pheochromocytoma, Carcinoma In Situ,
Location: Tacoma WA, Seattle WA, Portland OR, Vancouver,
Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 25

Code: NCT02402244

Recruiting

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for
Metastatic Malignant Neoplasm in the Lung,
Location: Tacoma WA, Renton WA, Seattle WA, Yakima WA,
Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 50

Code: NCT05235165

Phase3, Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for
Acute Myeloid Leukemia
Location: Tacoma WA, Seattle WA, Portland OR, Vancouver,
Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 21

Code: NCT04293562

Phase3, Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

for
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma,
Location: Tacoma WA, Spokane WA, Fullerton CA, Milwaukee WI,
Sponsor: Panbela Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05254171

Phase2, Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for
Triple Negative Breast Cancer
Location: Puyallup WA, Lacey WA, Portland OR, Corvallis OR,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase3, Recruiting

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

for
Spinal Muscular Atrophy (SMA)
Location: Tacoma WA, Seattle WA, Portland OR, Sacramento CA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 0+

Code: NCT04174157

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

for
Colitis, Ulcerative
Location: Tacoma WA, Seattle WA, Sacramento CA, Los Angeles CA,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 2 - 17

Code: NCT05076175

Phase2, Phase3, Recruiting

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

for
Type 1 Diabetes
Location: Tacoma WA, Seattle WA, San Francisco CA, Aurora CO,
Sponsor: SAb Biotherapeutics, Inc.

Sex: All

Age: 5 - 40

Code: NCT07187531

Phase2, Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Tacoma WA, Seattle WA, Olympia WA, Salem OR, Spokane WA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06692738

Phase3, Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

for
Diffuse Large B-Cell Lymphoma
Location: Tacoma WA, Des Moines IA
Sponsor: AstraZeneca

Sex: All

Age: 65 - 70+

Code: NCT05952024

Phase2, Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry

for
Lysosomal Acid Lipase Deficiency,
Location: Tacoma WA, Edmonton, Stanford CA, Phoenix AZ,
Sponsor: Alexion Pharmaceuticals, Inc.

Sex: All

Age: 0+

Code: NCT01633489

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for
Non-small Cell Lung Cancer (NSCLC)
Location: Tacoma WA, Vancouver, Grand Junction CO, Los Angeles CA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07291037

Phase3, Recruiting

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

for
Obesity, Overweight, Diabetes Mellitus, Type 2
Location: Tacoma WA, Renton WA, Bellevue WA, West Valley City UT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18 - 70+

Code: NCT07215559

Phase2, Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

for
Metastatic Colorectal Cancer (CRC)
Location: Tacoma WA, Spokane WA, Roseville CA, Vallejo CA,
Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT07228832

Phase3, Recruiting

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

for
Alzheimer Disease, Dementia, Plaque, Amyloid
Location: Tacoma WA, Bellevue WA, Boise ID, Sacramento CA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 55+

Code: NCT07602582

Phase3, Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for
Cardiovascular Disease
Location: Tacoma WA, Renton WA, Seattle WA, Redmond WA, Victoria,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07000357

Phase3, Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for
Advanced Breast Cancer
Location: Tacoma WA, Glendale CA, Los Angeles CA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06380751

Phase3, Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer
Location: Tacoma WA, Edmonton, Walnut Creek CA, Las Vegas NV,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06350097

Phase3, Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for
Non-Small Cell Lung Cancer
Location: Tacoma WA, Wenatchee WA, Vancouver WA, Vancouver,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06357533

Phase3, Recruiting